ADEMPAS® (riociguat) is licensed as monotherapy or in combination with endothelin receptor antagonists (ERA’s), for the treatment of adult patients with PAH with WHO Functional Class (FC) II to III to improve exercise capacity.1
ADEMPAS (riociguat) is also licensed for the treatment of adult patients with WHO functional class II to III with:
ADEMPAS® (riociguat)
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet
GB-ADE-00357 | Date of Preparation: May 2020